Hygienic Labs, an OTC drug manufacturer, failed to respond to FDA records requests.
What happened
FDA sent an electronic request for records under section 704(a)(4) to the firm’s registration contact email on September 27, 2022; a second email on October 12, 2022, and phone attempts on December 8 and 14, 2022, went unanswered. A UPS follow-up delivered February 7, 2023 was confirmed by the shipper, but the firm did not respond; a final phone attempt on September 15, 2023 reached a number no longer in service.
What FDA found
The firm refused to permit access to or copying of records requested by FDA under section 704(a)(4).
Section 301(e) of the FD&C Act (21 U.S.C. 331(e)); section 704(a)(4) (21 U.S.C. 374(a)(4))The firm did not respond to FDA’s records request or follow-up communications, leaving FDA without information on quality assurance for its registered OTC drugs.
Section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))
What FDA wants
FDA tells the firm to respond within 48 hours to confirm or update its registration and drug listing status and say whether it will answer the records request. If it no longer makes drugs, it must delist all drugs using the last lot expiration date as the marketing end date and deregister the facility.
Who should pay attention
- OTC drug manufacturers registered with FDA
- brands or distributors using small OTC drug manufacturers
- regulatory teams handling FDA records requests and drug listings
This is a summary. Read the original letter on fda.gov.